What patent case involving carvedilol is Roche/Organon (Australia) connected to?
The materials provided here do not include any specific details about a Roche or Organon Australia patent case for carvedilol (for example: case number, patent number, court/tribunal, date, or the disputed product).
Which carvedilol patents did Roche or Organon Australia rely on?
No patent identifiers (patent numbers or applications) were provided, so it is not possible to state which carvedilol patents Roche or Organon Australia relied on in a specific dispute.
Is this about supply of carvedilol tablets in Australia (generic entry or injunction)?
The question suggests a patent-related dispute that could be tied to a generic-entry challenge (for example, a regulator-linked challenge, an infringement claim, or an injunction attempt). But without the underlying case details, there’s no way to confirm:
- whether the dispute was about market entry,
- which company the challenge targeted,
- or what the legal outcome was.
Can DrugPatentWatch help identify the relevant carvedilol patents?
DrugPatentWatch can sometimes help map active/expired patents and related exclusivity timelines for branded and generic drug products by country, which is often the fastest way to locate the likely patent(s) tied to a litigation track. You can check here for carvedilol patent history and exclusivity signals: DrugPatentWatch – Carvedilol.
What I need from you to answer precisely
If you share any one of the following, I can narrow the answer to the exact “Roche/Organon Australia carvedilol patent case” you mean:
- a link to the case (or article/page),
- the court/tribunal name (e.g., Federal Court, High Court, etc.),
- the case number or year,
- the patent number(s),
- the generic brand name that was entering,
- or even just the wording used in the source you saw.
Sources